2011/09/16 by Junichi Kaneko, Yasuhiko Sugawara, Sumihito Tamura +4 · 1 citation
Medicine · #Liver Diseases and Immunity #Liver Disease and Transplantation #Organ Transplantation Techniques and Outcomes #Medicine #Primary biliary cirrhosis #Methylprednisolone #Liver transplantation #Liver biopsy #Internal medicine #Gastroenterology #Tacrolimus #Cirrhosis #Biopsy #Outpatient clinic #Survival rate #Transplantation #Surgery
paper · doi:10.1111/j.1432-2277.2011.01336.x
openalex publication_date 2011/09/16 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/23
In living donor liver transplantation (LDLT) for primary biliary cirrhosis (PBC), the majority of donors are genetically related to their recipients, leading to concerns of an earlier recurrence of PBC and a poorer prognosis due to genetic susceptibility. Totally 81 patients who underwent LDLT for PBC were the subjects of the present study. Immunosuppressive agents consisted of tacrolimus and methylprednisolone. In the outpatient clinic, when the aspartate and alanine aminotransferase level exceeded the upper limit of the normal range, the dose of methylprednisolone was increased from 4 to 6 mg/day for several months. Blood was examined every 2 weeks for 3 months and a liver biopsy was performed when aminotransferase levels did not decrease to the upper limit of the normal range after more than 3 months. Five-year survival and recurrence rates were estimated and the prognostic factors were analyzed. The mean observation period was 6.2 years. Five years after LDLT for PBC, the biopsy-proven PBC recurrence rate was 1%. The 5-year patient survival rate was 80%. The nonrelated or blood-related donor factor and number of human leukocyte antigen matches did not correlate with prognosis. PBC recurrence rate after LDLT in our series was lower than that in previous studies.